External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Momentum in Pharma and F&amp;F Segment: The pharma division witnessed strong momentum in Q4, with sales nearly tripling to Rs 6.67 Cr compared to Q3, crossing the break-even threshold and beginning to contribute positively to profitability.</li><li>For FY26, the management is targeting revenue of Rs 30–35 Cr from the pharma segment, supported by planned capacity expansions and product diversification by Q1/Q2 FY26.</li><li>With enhanced IML printing capacities, the F&amp;F segment recorded robust sales growth of 25.5% in Q4.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Momentum in Pharma and F&amp;F Segment: The pharma division witnessed strong momentum in Q4, with sales nearly tripling to Rs 6.67 Cr compared to Q3, crossing the break-even threshold and beginning to contribute positively to profitability.For FY26, the management is targeting revenue of Rs 30–35 Cr from the pharma segment, supported by planned capacity expansions and product diversification by Q1/Q2 FY26.With enhanced IML printing capacities, the F&amp;F segment recorded robust sales growth of 25.5% in Q4.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Mold-Tek Packaging - Turn Around Ahead; Maintain BUY

Mold Tek Packaging

Mold-Tek Packaging - Turn Around Ahead; Maintain BUY